Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dissociable somatotopic representations of Chinese action verbs in the motor and premotor cortex.

Scientific reports·2013

Same author

High quantum-yield CdSexS1-x/ZnS core/shell quantum dots for warm white light-emitting diodes with good color rendering.

Nanotechnology·2013

Same author

Osteopontin mediating cyclosporine A induced epithelial-to-mesenchymal transition on rat renal tubular epithelial cells.

Cell biology international·2013

Same author

A novel microfluidic mixer based on dual-hydrodynamic focusing for interrogating the kinetics of DNA-protein interaction.

The Analyst·2013

Same author

Correlation of reorientational jumps of water molecules in bulk water.

Physical review. E, Statistical, nonlinear, and soft matter physics·2013

Same author

Palladium-catalyzed direct arylation of C-H bond to construct quaternary carbon centers: the synthesis of diarylfluorene.

Organic letters·2013

Search research articles

Related Experiment Video

Updated: May 13, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Methotrexate for ankylosing spondylitis.

Junmin Chen¹, Mirella M S Veras, Chao Liu

¹Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. drjunminchen@hotmail.com.

The Cochrane Database of Systematic Reviews

|March 2, 2013

Summary

Methotrexate (MTX) shows limited evidence for treating ankylosing spondylitis (AS). While one trial indicated a benefit in response rates, overall results did not demonstrate significant advantages over no MTX treatment.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Area of Science:

Rheumatology
Clinical Pharmacology
Evidence-Based Medicine

Background:

Ankylosing spondylitis (AS) is a chronic inflammatory condition affecting the spine.
Methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD), is effective in rheumatoid arthritis (RA).
This review updates previous assessments of MTX for AS treatment.

Purpose of the Study:

To evaluate the efficacy and safety of methotrexate (MTX) for treating ankylosing spondylitis (AS).

Main Methods:

Searched multiple databases (CENTRAL, MEDLINE, EMBASE, Scopus) up to June 2012.
Included randomized controlled trials (RCTs) and quasi-randomized controlled trials (qRCTs).
Two authors independently extracted data and assessed risk of bias; disagreements were resolved by a third author.

Main Results:

Three RCTs with 116 participants were included; only one was at low risk of bias.
No statistically significant differences favoring MTX were found for most outcomes.
One trial showed a significant response rate benefit (36% absolute benefit, NNT=3) for MTX versus placebo, based on a composite index.

Conclusions:

Insufficient evidence supports the use of MTX for AS treatment.
High-quality RCTs with larger sample sizes are required to determine MTX's effects on AS.